Opinion|Videos|October 24, 2024
Impact of Comorbidities on IPF Management
Author(s)Toby Maher, MD, PhD
Key Takeaways
- Comorbidities can obscure IPF symptoms, leading to diagnostic delays or misdiagnoses, complicating the clinical presentation.
- Comprehensive evaluation is crucial to tailor treatment plans addressing both IPF and comorbidities effectively.
Toby Maher, MD, PhD, discusses how comorbidities complicate the diagnosis and management of idiopathic pulmonary fibrosis (IPF) and influence treatment decisions, highlighting the need for a comprehensive approach in patient care.
Advertisement
Episodes in this series
Video content above is prompted by the following:
How do comorbidities affect diagnosis and management of IPF? In what ways do comorbidities affect treatment decisions?
Advertisement
Related to this article
Machine learning identified age, BMI, income, and reproductive factors as key predictors of overactive bladder risk among US women.
Tammy Lundstrom, MD, JD, discusses the new childhood vaccine order, single-dose MMR access concerns, and the measles resurgence.
Twice-daily dosing of the oral JAK inhibitor deuruxolitinib nearly tripled response rates over once-daily dosing in severe alopecia areata.
Clinicians pair CD20×CD3 bispecifics with radiotherapy in relapsed B‑cell lymphoma, but data stay sparse—early safety signals prompt trials.
Panelists at NASP inSPire2026 said specialty pharmacies could close clinical trial enrollment gaps by capturing one missed data point.
“I think there’s not a lot of information as to what the process is for individuals who have questions about that,” explains Kerry Rogers, MD.
Across 29,132 surgically treated T1 cases, lymph node metastasis hit 19.2% under age 50 vs 11.1% at 50 and older.
Imlunestrant plus abemaciclib doubled median PFS in patients with ESR1-mutated advanced breast cancer.
Advertisement
Advertisement
Trending on AJMC
1
Surrogate End Points, Drug Costs Complicate Oncology Formularies
2
COVID-19 or Flu? Symptoms Alone Can't Tell: Tammy Lundstrom, MD, JD
3
Perceptions About CGMs Among Primary Care Physicians and Endocrinologists
4
Medicare Part D Ruxolitinib Spending Hits $49.6 Million as Use Surges
5